667, L.P. bought $24.0M of Immunocore (IMCR)

Executed Mar 17 2025, disclosed Mar 19 2025, 2 days later.

Value, as filed

$24.0M

807,338 sh across 4 lots

Executed

Mar 17 2025

the trade date, as filed

Disclosed

Mar 19 2025

2 days after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

-3.0%

-6.0% from execution

Over the 21 trading sessions from the disclosed entry session (Mar 19 2025), the stock returned -3.0% (delay-adjusted); from the execution session (Mar 17 2025), -6.0%. Derived: entry at the session's open, exit at the close 20 sessions later.

The filer

LP 667, L.P. Director profile →

667, L.P. (Director) filed 1 Form 4 report as a reporting entity in the past 24 months (1 purchase, 0 sales), most often in IMCR. Across 1 priced purchase filing, the average 21-session return was -6.0% from execution and -3.0% from disclosure (delay-adjusted; derived). The largest single filing was $24.0M of IMCR (807,338 sh across 4 lots, as filed), executed Mar 17 2025.

The name

IMCR IMCR IMCR · 9 filings in 24 months ticker → Insider filings, newest first→ View the original filing at www.sec.gov→